Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2019, Article ID 4903671, 12 pages
Review Article

Effectiveness and Safety of Oral Cordyceps sinensis on Stable COPD of GOLD Stages 2–3: Systematic Review and Meta-Analysis

1The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China
2School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia

Correspondence should be addressed to Charlie Changli Xue; ua.ude.timr@eux.eilrahc and Yinji Xu; moc.361@ijniyux

Received 8 November 2018; Accepted 25 February 2019; Published 3 April 2019

Academic Editor: Deborah A. Kennedy

Copyright © 2019 Xuhua Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Cordyceps sinensis (CS) is a complementary medicine used for Chronic Obstructive Pulmonary Disease (COPD) of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 2-3. Many randomized controlled trials have been conducted to evaluate the effect of CS alone or in combination with other herbs on stable COPD. To provide a synthesis of the evidence, we searched nine major electronic databases for randomized controlled trials on CS published before 21st December 2016. Fifteen interventional studies, including 1,238 participants, met the inclusion criteria. Meta-analysis showed that both CS preparations and CS formulae showed the potential benefits in lung function, exercise endurance, life quality, and improvement of symptoms. No serious adverse events were reported. So CS may be a promising treatment for patients with stable COPD of GOLD stages 2-3. No studies were placebo-controlled or of high methodological quality, which limits the conclusions.